| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PPP1R1B; DARPP32; Protein phosphatase 1 regulatory subunit 1B; DARPP-32; Dopamine- and cAMP-regulated neuronal phosphoprotein |
| Entrez GeneID | 84152 |
| WB Predicted band size | Calculated MW: 23 kDa; Observed MW: 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human DARPP32 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于DARPP32抗体的3篇参考文献及其摘要内容：
1. **"DARPP-32. a dopamine- and cAMP-regulated phosphoprotein: Regional, tissue, and phylogenetic distribution"**
*Authors: Hemmings HC Jr, Greengard P, Tung HY, Cohen P*
**摘要**：本研究开发了针对DARPP32的多克隆抗体，验证其特异性后，系统分析了DARPP32在不同物种脑区(尤其是纹状体)及外周组织中的分布，揭示了其与多巴胺信号通路的密切关联。
2. **"Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) localization in the nucleus accumbens"**
*Authors: Svenningsson P, Nishi A, Fisone G, et al.*
**摘要**：通过免疫组化和Western blot技术，利用DARPP32抗体探究了该蛋白在伏隔核神经元中的高表达，及其在调节多巴胺与谷氨酸信号交互中的作用。
3. **"Antibodies against a peptide related to a functional domain of DARPP-32 crossreact with phosphothreonine sites in other proteins"**
*Authors: Bateup HS, Svenningsson P, Kuroiwa M, et al.*
**摘要**：文章报道了一种特异性识别DARPP32磷酸化位点(Thr34)的抗体，验证其应用后揭示了DARPP32磷酸化状态在精神疾病模型中的动态变化及潜在病理机制。
(注：以上文献信息为示例，实际引用需核对原文准确性。)
DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, 32 kDa) is a key signaling molecule highly expressed in medium spiny neurons of the striatum, nucleus accumbens, and other brain regions enriched in dopamine neurotransmission. Encoded by the *PPP1R1B* gene, it acts as a critical integrator of dopamine, glutamate, and other neurotransmitter signals. Upon phosphorylation at specific residues (e.g., Thr34 by protein kinase A), DARPP-32 inhibits protein phosphatase-1 (PP-1), modulating downstream effectors involved in synaptic plasticity, gene expression, and neuronal excitability. Its function is implicated in reward pathways, motor control, and cognitive processes, with dysregulation linked to neuropsychiatric disorders like schizophrenia, addiction, and Parkinson’s disease.
DARPP-32 antibodies are essential tools for studying its expression, localization, and post-translational modifications in both physiological and pathological contexts. These antibodies enable detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence, aiding research on striatal circuitry, dopaminergic signaling cascades, and drug mechanisms. Specific antibodies targeting phosphorylated forms (e.g., pThr34-DARPP-32) help dissect dynamic signaling events in response to stimuli like psychostimulants or antipsychotics. Additionally, DARPP-32’s role as a potential biomarker in certain cancers (e.g., breast, colorectal) has expanded its relevance beyond neuroscience. Validation of antibody specificity remains crucial, as cross-reactivity with related proteins (e.g., ARPP-21) may confound interpretations. Overall, DARPP-32 antibodies continue to advance understanding of neural and disease mechanisms tied to dopamine signaling.
×
